Adma Biologics reported $33.74M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Adma Biologics USD 33.74M 16.65M Mar/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
Minerva Neurosciences 386K 31K Jun/2024
Novavax USD 22.1M 608K Dec/2025
Omeros USD 33.16M 18.52M Jun/2024
Takeda JPY 517.6B 42.94B Jun/2026